Search results
Qi-Ming He University of Waterloo. Donglei Du Professor of Operations Research, University of New Brunswick. Cristian Dobre Tilburg University. Follow. Juan C. Vera. Professor Tilburg University. Verified email at uvt.nl - Homepage. Optimization Polynomial Programming Combinatorics. Title.
Juan Vera is a Paraguayan midfielder who plays for Chacarita Juniors in Argentina. He made his professional debut in 2019 and has one appearance for the club in the Primera B Nacional.
View Juan Vera’s profile on LinkedIn, a professional community of 1 billion members. To the edge of machine intelligence // alumn @ TKS // ce @ UC Davis (on gap) · I opted out of UC Davis to ...
- 395
- The Knowledge Society (TKS)
- Seneca Valley High School
- Gaithersburg, Maryland, United States
Juan F. Vera, M.D. Chief Executive Officer For the past 19 years, Dr. Vera has worked extensively on developing novel T cell therapies for clinical applications and has an extensive expertise in performing research in the field of adoptive T cell therapy.
- 2450 Holcombe Blvd. Suite BCM-A, MS: BCM251, Houston, 77021, TX
- (713) 400-6400
- The Last 12 Months of Insider Transactions at Marker Therapeutics
- Insider Ownership of Marker Therapeutics
- So What Do The Marker Therapeutics Insider Transactions indicate?
- GeneratedCaptionsTabForHeroSec
Notably, that recent purchase by Juan Vera is the biggest insider purchase of Marker Therapeutics shares that we've seen in the last year. Even though the purchase was made at a significantly lower price than the recent price (US$2.58), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular ...
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Insiders own 13% of Marker Therapeutics shares, worth about US$32m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between managem...
It's certainly positive to see the recent insider purchases. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Marker Therapeutics we think they are probably pretty confident o...
Juan Vera, Chief Development & Scientific Officer and Director of Marker Therapeutics, Inc. (NASDAQ:MRKR), purchased US$1m worth of stock at an average price of US$1.75. The company is a biotechnology company that develops cell therapies for cancer and autoimmune diseases.
Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for th...
- 10 min
- 167
- HPR
Juan Vera is known for his work on An Unexpected Love (2018), 2 + 2 (2012) and Cops and Robbers (1994).
